How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

The growing prevalence of diabetes, primarily due to obesity, aging populations, and sedentary lifestyles, is a key factor ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

A study from the Arkansas Agricultural Experiment Station finds that GLP-1 medications, such as Ozempic and Wegovy, are ...

Five researchers have been jointly awarded one of this year's Breakthrough Prizes in Life Sciences for their contributions to the development of Ozempic-style drugs.

Studies show that GLP-1 agonists can help patients lose 5-15% of their body weight when combined with diet and exercise.

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Glucagon-like peptide 1 ... Piece by piece, they gathered data showing that the hormone stimulated insulin secretion, and that it inhibited food intake and the emptying of the stomach after ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Linda Gigliotti, MS, RDN, CDCES, FAND, about combining the use of GLP-1 ...